XERS Stock Analysis: Xeris Pharmaceuticals | NASDAQ

Hypoglycemia, Periodic Paralysis, Cushings Syndrome, Hypothyroidism

Total Rating 40

Safety 29

Buy Signal 0.61

Drug Manufacturers - Specialty & Generic
Industry Rotation: +2.2

Market Cap: 1.88B
Avg Turnover: 27.3M

Risk 3d forecast

Volatility52.1%

VaR 5^th Pctl8.31%

VaR vs Median-3.12%

Reward TTM

Sharpe Ratio0.41

Rel. Str. IBD90.2

Rel. Str. Peer Group83.3 pctl

Character TTM

Beta0.609

Beta Downside-0.121

Hurst Exponent0.438

Choppyness46.7%

Drawdowns 3y

Max DD47.20%

CAGR/Max DD1.82

CAGR/Mean DD4.77

EPS (Earnings per Share)

Last SUE: -1.38
Qual. Beats: -1

Revenue

Rev. CAGR: 34.30%
Rev. Trend: 99.4%

Last SUE: 0.90
Qual. Beats: 2

Warnings

High Debt/EBITDA With Thin Interest Coverage

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 8.3 years of data

Jan -2.0% 21

Feb +3.3% 12

Mar -4.5% 6

Apr +0.8% 9

May +1.7% 9

Jun -0.0% 2

Jul +1.1% 14

Aug +5.5% 18

Sep -1.3% 27

Oct -0.6% 6

Nov +1.0% 6

Dec +1.4% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: XERS Xeris Pharmaceuticals

Xeris Biopharma Holdings, Inc. (XERS) is a commercial-stage biopharmaceutical company headquartered in Chicago, Illinois, focused on developing and commercializing therapies for chronic endocrine and neurological diseases. The company was incorporated in 2005 and has been listed on NASDAQ since its IPO in June 2018, currently operating with a small-cap market capitalization in the U.S. healthcare sector. As a commercial-stage biopharmaceutical firm, Xeris generates revenue from approved products while also advancing a pipeline candidate through clinical development.

The companys commercial portfolio includes Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous Cushings syndrome. In addition, Xeris is developing XP-8121, a once-weekly subcutaneous levothyroxine injection currently in Phase 3 clinical trials for hypothyroidism. Specialty biopharmaceutical companies operating in rare and chronic disease areas typically depend on a small number of approved products, making pipeline progression and regulatory approvals critical to long-term growth.

Headlines to Watch Out For

Gvoke glucagon sales growth competes with Baqsimi in hypoglycemia market
Recorlev launch accelerates in Cushings syndrome treatment
XP-8121 phase 3 hypothyroidism data readout approaches

Piotroski VR-10 (Strict) 5.0

Net Income: -17.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA 18.46 > 1.0
NWC/Revenue: 25.40% < 20% (prev 36.75%; Δ -11.35% < -1%)
CFO/TA 0.14 > 3% & CFO 56.6m > Net Income -17.2m
Net Debt (204.5m) to EBITDA (16.6m): 12.33 < 3
Current Ratio: 1.45 > 1.5 & < 3
Outstanding Shares: last quarter (172.8m) vs 12m ago 10.80% < -2%
Gross Margin: 83.34% > 18% (prev 81.14%; Δ 2.21% > 0.5%)
Asset Turnover: 89.85% > 50% (prev 73.51%; Δ 16.34% > 0%)
Interest Coverage Ratio: 0.14 > 6 (EBIT TTM 3.93m / Interest Expense TTM 28.3m)

Altman Z'' -4.14

A: 0.21 (Total Current Assets 274.8m - Total Current Liabilities 189.6m) / Total Assets 411.9m
B: -1.70 (Retained Earnings -700.2m / Total Assets 411.9m)
C: 0.01 (EBIT TTM 3.93m / Avg Total Assets 373.3m)
D: -0.02 (Book Value of Equity -9.73m / Total Liabilities 421.6m)
Altman-Z'' = -4.14 = D

Beneish M -3.12

DSRI: 0.80 (Receivables 58.1m/53.0m, Revenue 335.4m/246.0m)
GMI: 0.97 (GM 81.14% / 83.34%)
AQI: 0.74 (AQ_t 0.27 / AQ_t-1 0.36)
SGI: 1.36 (Revenue 335.4m / 246.0m)
TATA: -0.18 (NI -17.2m - CFO 56.6m) / TA 411.9m)
Beneish M = -3.12 (Cap -4..+1) = AA

What is the price of XERS shares?

As of October 26, 2026, the stock is trading at USD 10.20 with a total of 2,372,225 shares traded. Over the past week, the price has changed by -1.07%, over one month by +17.78%, over three months by +21.28% and over the past year by +11.72%.

Current recommended Stop Loss: 9.50 (which is 6.9% or 1.3 ATR below the current price).

Is XERS a buy, sell or hold?

Xeris Pharmaceuticals has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy XERS.

StrongBuy: 5
Buy: 1
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the XERS price?

Analysts Target Price	12.9	26.1%

Xeris Pharmaceuticals (XERS) - Fundamental Data Overview as of 19 October 2026

Market Cap USD = 1.88b (1.88b USD * 1.0 USD.USD)
P/E Forward = 36.9004
P/S = 5.6042
P/B = 107.6774
Revenue TTM = 335.4m USD
EBIT TTM = 3.93m USD
EBITDA TTM = 16.6m USD
Long Term Debt = 188.8m USD (from longTermDebt, last quarter)
Short Term Debt = 70.1m USD (from shortTermDebt, last quarter)
Debt = 326.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 36.9m
Net Debt = 204.5m USD (calculated: Debt 326.3m - CCE 121.7m)
Enterprise Value = 2.08b USD (1.88b + Debt 326.3m - CCE 121.7m)
Interest Coverage Ratio = 0.14 (Ebit TTM 3.93m / Interest Expense TTM 28.3m)
EV/FCF = 37.64x (Enterprise Value 2.08b / FCF TTM 55.4m)
FCF Yield = 2.66% (FCF TTM 55.4m / Enterprise Value 2.08b)
FCF Margin = 16.51% (FCF TTM 55.4m / Revenue TTM 335.4m)
Net Margin = -5.12% (Net Income TTM -17.2m / Revenue TTM 335.4m)
Gross Margin = 83.34% ((Revenue TTM 335.4m - Cost of Revenue TTM 55.9m) / Revenue TTM)
Gross Margin QoQ = 86.41% (prev 84.02%)
Tobins Q-Ratio = 5.06 (Enterprise Value 2.08b / Total Assets 411.9m)
Interest Expense / Debt = 8.66% (Interest Expense 28.3m / Debt 326.3m)
Taxrate = 0.0% (0.0 / 554k)
NOPAT = 3.93m (EBIT 3.93m * (1 - 0.00%))
Current Ratio = 1.45 (Total Current Assets 274.8m / Total Current Liabilities 189.6m)
Debt / Equity = -33.52 (negative equity) (Debt 326.3m / totalStockholderEquity, last quarter -9.73m)
Debt / EBITDA = 12.33 (Net Debt 204.5m / EBITDA 16.6m)
Debt / FCF = 3.69 (Net Debt 204.5m / FCF TTM 55.4m)
Total Stockholder Equity = 4.03m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.60% (Net Income -17.2m / Total Assets 411.9m)
RoE = -426.3% (Net Income TTM -17.2m / Total Stockholder Equity 4.03m)
RoCE = 2.04% (EBIT 3.93m / Capital Employed (Equity 4.03m + L.T.Debt 188.8m))
RoIC = 1.43% (NOPAT 3.93m / Invested Capital 275.7m)
WACC = 7.83% (E(1.88b)/V(2.21b) * Re(7.69%) + D(326.3m)/V(2.21b) * Rd(8.66%) * (1-Tc(0.0)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.75 | Cagr: 9.63%
[DCF] Terminal Value 75.44% ; FCFF base≈55.4m ; Y1≈55.6m ; Y5≈58.9m
[DCF] Fair Price = 3.90 (EV 916.2m - Net Debt 204.5m = Equity 711.6m / Shares 182.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.38 | # QB: -1
Revenue Correlation: 99.38 | Revenue CAGR: 34.30% | SUE: 0.90 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.03 | Chg30d=N/A | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.02 | Chg30d=N/A | Revisions=-25% | GrowthEPS=+0.0% | GrowthRev=+32.9%
EPS next Year (2027-12-31): EPS=0.37 | Chg30d=-5.13% | Revisions=-25% | GrowthEPS=+2319.6% | GrowthRev=+23.8%
[Analyst] Revisions Ratio: -50% (up=0, down=3)